39 patents
Page 2 of 2
Utility
Mescaline Derivatives with Modified Action
23 Mar 23
A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R′ is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Z allylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.
Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
Filed: 28 Nov 22
Utility
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
9 Mar 23
A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet.
Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT
Filed: 17 Aug 22
Utility
18-MC for treatment of substance use disorders
7 Mar 23
A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier.
Scott Freeman, Stots B. Reele, Jeanne Bonelle
Filed: 1 Oct 20
Utility
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
2 Mar 23
A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet.
Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL
Filed: 17 Aug 22
Utility
Synthesis Routes to Access Mdma Prodrugs by Using Controlled and Non-controlled Intermediates
2 Mar 23
A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior.
Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
Filed: 23 Aug 22
Utility
System and Method for Automatic Analysis of Texts In Psychotherapy, Counseling, and Other Mental Health Management Activities
23 Feb 23
A method of analyzing a patient's mental state, by automatically processing, integrating, and analyzing text-based and audio-based sources from the patient and clinical staff, and generating real-time outcomes and predictions.
Adam KOLAR, Martin MAJERNIK, Miguel Amavel dos Santos PINHEIRO, Daniel R. KARLIN, Robert BARROW
Filed: 17 Aug 22
Utility
System and Method for Monitoring a Consciousness-altering Therapeutic Session
5 Jan 23
A system for monitoring patients during a consciousness-altering therapeutic treatment session including a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session.
Martin MAJERNIK, Daniel R. KARLIN, Robert BARROW, Peter DUBEC
Filed: 13 Jun 22
Utility
18-MC for Treating Obesity
29 Dec 22
A method of treating obesity, by administering an effective amount of a composition chosen from the group consisting of 18-methoxycoronaridine (18-MC), salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, homologues thereof, and deuterated forms thereof to an individual and treating obesity.
Robert BARROW, Daniel R. KARLIN
Filed: 8 Jun 22
Utility
System and method for patient monitoring of gastrointestinal function using automated stool classifications
20 Dec 22
A method of data collection of stool data via a mobile device operable to enable monitoring of gastrointestinal function.
Daniel R Karlin, Peter Dubec, Martin Majernik, Vladimir Boza, Lucia Kvapilova, Dana Rajtarova
Filed: 12 Jun 20
Utility
Controlling Effects after 5HT2A Agonists Administration
15 Dec 22
A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent.
Daniel R. KARLIN, Robert BARROW
Filed: 6 Jun 22
Utility
Formulations of Psilocin That Have Enhanced Stability
24 Nov 22
A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability.
Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER, Gerald S. JONES, JR.
Filed: 8 Aug 22
Utility
Psychedelics for Treatment of Pain
17 Nov 22
A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual.
Robert BARROW, Daniel R KARLIN
Filed: 29 Jul 22
Utility
Mdma Enantiomers
10 Nov 22
A composition for use in psychotherapeutic or medical treatment of an R(−) enantiomer of MDMA or MDA.
Robert BARROW, Daniel R. KARLIN
Filed: 1 May 22
Utility
Movement Disorders
10 Nov 22
A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.
Robert BARROW, Daniel R. KARLIN
Filed: 1 May 22
Utility
Liposome Delivery of Psychedelics
10 Nov 22
A composition of a psychedelic in a liposome formulation, wherein the composition provides preferential distribution of the psychedelic at the CNS and blood, and reduced distribution at peripheral organs.
Robert BARROW, Gennady N. SMAGIN
Filed: 29 Apr 22
Utility
Psychedelics for Treatment of Pain
3 Nov 22
A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual.
Robert BARROW, Daniel R KARLIN
Filed: 29 Apr 22
Utility
LSD Salt Crystal Forms
3 Nov 22
Polymorphic forms of lysergic acid diethyl amide (LSD) in crystalline salt forms.
Daniel Emil LEVY, Stephen E. SCHNEIDER
Filed: 26 Apr 22
Utility
Formulations of Psilocin That Have Enhanced Stability
8 Sep 22
A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability.
Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER
Filed: 4 Mar 22
Utility
Mescaline Derivatives with Modified Action
25 Aug 22
A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R′ is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Z allylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.
Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
Filed: 20 Feb 22